<DOC>
	<DOCNO>NCT00494624</DOCNO>
	<brief_summary>We predict wheeze child young 3 year age benefit systemic glucocorticoid one . It know whether difference efficacy related difference viral etiology , atopy , immunogical maturity age patient . The study aim answer follow question : 1 . What viral etiology acute childhood expiratory wheeze ? 2 . What efficacy prednisolone relation age , atopy viral etiology acute childhood wheeze ? 3 . Does prednisolone treatment increase risk secundary bacterial infection acute childhood expiratory wheeze ? 4 . What significance inflammatory marker predict efficacy systemic steroid patient outcome acute childhood expiratory wheeze ? Study follow randomize , double blind , placebo-controlled parallel design . Study start Septemper 2000 perform Department Pediatrics , Turku University Hospital , Turku Finland . The study population 300 hospitalize wheeze child age 3 month – 15 year . Investigational drug prednisolone , first dose 2 mg/kg , 2 mg/kg/d/3 ( max . 60 mg/vrk ) p.o . 3 comparative drug placebo tablet similar investigational drug equal dosage . The primary outcome time ready discharge . The study provide new important information diagnostics , treatment , disease outcome prevention acute childhood expiratory wheezing .</brief_summary>
	<brief_title>Efficacy Systemic Glucocorticoid Treatment Wheezing Children</brief_title>
	<detailed_description>Introduction Extensive survey show 6-20 % child acute expiratory wheezing ( 1 , 2 ) . The lifetime prevalence wheezing among 12–14-year-old child Western country 8-19 % ( 3 , 4 ) . The clinical illness call bronchiolitis occur first time infant younger 12 month ( 5 ) . When occur later recur , beside bronchiolitis diagnosis wheezy bronchitis use ( 6 ) . In old child wheezy bronchitis distinguish virus-induced-asthma . In many country first expiratory wheeze attack age &gt; 3 year diagnose asthma . To extent , bronchiolitis , wheezy bronchitis , asthma expression pathologic process present rigid criterion separate three illness . Acute bronchiolitis commonly cause respiratory syncytial virus ( RSV ) wheezy bronchitis rhinovirus infection ( 6 - 8 ) . Exacerbations asthma induce 80-85 % case viral respiratory infection child , mostly rhinovirus infection ( 7 , 9 ) . It well establish systemic glucocorticoid cornerstone management acute asthma ( 10 ) . However , systemic glucocorticoid appear effective bronchiolitis young child ( 11 ) . Despite lack evidence efficacy , glucocorticoid use 60 % patient RSV bronchiolitis ( 12 ) . The unfavourable effect glucocorticoid viral infection receive increase attention . For example , steroid find increase risk acute otitis medium rhinovirus infection child ( 13 ) . In adults glucocorticoid increase titer rhinovirus shed virus pharynx ( 14 , 15 ) . It may possible glucocorticoid increase severity viral respiratory tract infection . Today , predict wheeze child young 3 year age benefit systemic glucocorticoid one . It know whether difference efficacy related difference viral etiology , atopy , immunogical maturity age patient . Main Questions 1 . What viral etiology acute childhood expiratory wheeze ? 2 . What efficacy prednisolone relation age , atopy viral etiology acute childhood expiratory wheeze ? 3 . Does prednisolone treatment increase risk secundary bacterial infection acute childhood expiratory wheeze ? 4 . What significance inflammatory marker predict efficacy systemic steroid patient outcome acute childhood expiratory wheeze ? Rationale The study provide new important information diagnostics , treatment , disease outcome prevention acute childhood expiratory wheeze . Design set Study follow randomize , double blind , placebo-controlled parallel design . Study start Septemper 2000 continue June 2002 ( except June July 2001 ) . The study perform department pediatrics , Turku University Central Hospital , Turku Finland . Subjects The study population 300 patient . To allow detection 18-h difference ( half average duration stay hospital ) time ready discharge prednisolone-treated group placebo group ( estimate standard deviation 24 h ) maintain alpha error 0.05 beta error 0.20 , require size sample 27 child treatment group RSV bronchiolitis ( 16 ) . No estimate available rhinovirus group . If patient separate different group accord e.g . age viral infection , 108 patient need . On hand get 31 patient viral infection ( viral infection 80 % patient expiratory wheezing , sensitivity method 69 % ) , 49 child need treatment group ( assess different subgroup , 196 child ) ( 9 , 17 ) . To take account variation epidemic , total 300 child recruit . The estimated time get enough patient , need hospitalization expiratory wheezing , 2 year department pediatrics , Turku University Central Hospital , Turku , Finland . Inclusion criterion - age 3 month 16 year - hospitalization expiratory wheeze - write informed consent parent Exclusion criterion - Any chronic disease ( allergy asthma ) , e.g . heart disease , immune deficiency , diabetes - varicella exposure varicella previously - Systemic glucocorticoid 4 week prios study - Severe disease need treatment intensive care unit oxygen saturation 92 % despite additional oxygen frequent salbutamol inhalation Study drug Investigational drug Prednisolone , first dose 2 mg/kg , 2 mg/kg/d/3 ( max . 60 mg/vrk ) p.o . 3 ( 5 mg tabletti , Prednisolon ® , Leiras , Finland ) . Comparative drug Placebo tablet similar investigational drug ( tablet , Leiras ) give equal dosage . Addministration drug Tablets cut four piece , mixt jelly ot yogurt . If child vomit , drug give 30 min . If child still vomit , give equal dose methylprednisolone physiologic saline i.v . i.m . ( 62,5 mg/ml inject , Solomet® , Orion , Finland ) . Randomization The randomization perform independent person participate study . According randomization , volunteer allocate one treatment . Individual number 01 onwards assign . Protocol The study physician inform subject guardian study give subject information ( Appendix 1 ) . Guardian ’ write informed concent ( Appendix 2 ) obtain get acquainted test procedure . The subject withdraw consent study time . Guardian ask fill modify ISAAC questionaire ( Appendix 3 ) . New patient enter study 8-10 a.m. p.m . The study outline study flow sheet ( Appendix 4 ) . The study physician examine patient twice daily 8-10 a.m. p.m. hospitalization ( Appendix 5 ) . The patient hospitalize wheeze breathing difficulty . After hospitalization patient fill symptom diary 2 week ( Appendix 6 ) . Follow-up visit 2 week hospitalization follow-up telephone contact 2 month hospitalization . If patient first wheeze episode , re-examined 12 month study oscillometric examination perform ( old 24 month ) . Nasal swap virological study also perform 60 healthy control child outpatient clinic surgical department Turku University Central Hospital study period . Methods Nasopharyngeal swap sample virologic study collect 3 sterile cotton swap dip nostril nasal mucosa . These sample place separate viral transport medium tube antigen , culture PCR analysis . Virus culture ( influenza A B , adeno- , RS- , parainfluenza type 1 , 2 3 virus ) do use Ohio strain HeLa cell human foreskin fibroplasts accord routine procedure . Viral antigen ( influenza A B , adeno- , RS- , parainfluenza type 1 , 2 3 virus ) detect time-resolved fluoroimmunoassay monoclonal antibody ( 17 ) . Reverse transcription-PCR assay use detection corona- , rhino- , entero- , RS- , influenza A B well human metapneumovirus ( hMPV ) . The detail method discribed earlier ( 18 , 19 ) . Virus-specific serum antibody titer ( Influenza A B virus , adenovirus , parainfluenza type 1/3 2 virus , RSV , HHV-6 enterovirus IgG well enterovirus also IgM ) determine enzyme immunoassay ( EIA ) use antigen-coated solid phase horsedish peroxidase conjugate rabbit antihuman IgG ( Dako , Glostrup , Denmark ) . Three fold increase IgG antibody titer consider positive except four fold increase RSV IgG antibody titer . Enterovirus also consider positive virus specific IgM positive . The influenssa A ja B , adeno , parainfluenssa type 1 , 2 3 well respiratory synsytial virus ( RSV ) antigen culture , rhino- , entero- coronavirus PCR perform Department Virology , Turku university , Finland . Human metapneumovirus PCR perform Department Virology , Erasmus Medical Center , Rotterdam , The Netherlands . RSV A B well Influenza virus A B PCR perform National Health Institute , Helsinki , Finland . Viral bacteral ( C. pneumoniae , M. pneumoniae , S. pneumoniae , H. influenzae ja M. catarrhalis ) perform National Health Institute , Oulu , Finland ( 17 ) . Expiratory nitric oxide collect bed side bag collection system ( Siemens ) analyse within 72 h Department Clinical Physiology , Turku University Central Hospital , Turku , Finland ( 20 ) . Oscillometric study perform Department Paediatric Turku University Central Hospital , Turku , Finland . Nasal cytokine ( IL-8 RANTES ) measurement perform Children ’ Hospital , University Texas Medical Branch , Galveston , Texas , USA . Other laboratory test perform Central Laboratory , Turku University Central Hospital , Turku , Finland . Primary endpoint : Our primary endpoint time ready discharge , define duration respiratory symptom score &gt; 3 hospital stay . The respiratory symptom score , assess every 12 h hospitalization , consist degree dyspnea ( 0=none , 1=mild , 2=moderate , 3=severe ) , type breathing ( 0=normal , 1=use stomach muscle , 2=use intercostal muscle , 3=nasal flaring ) , severity auscultatory finding wheeze ( 0=none , 1=expiratory , 2=inspiratory expiratory , 3=audible without stethoscope ) , assessment expiratory : inspiratory time ( 0=1:2 , 1=1:1 , 2=2:1 , 3=3:1 ) . An estimation 6 h use last 12 h period hospital assessment , i.e . period patient become ready discharge . Secondary endpoint : Oxygen saturation hospital stay , wheeze cough two week discharge hospital ( assessed day none , mild , moderate severe ) , readmission out-patient clinic hospital recurrent wheeze two-month period discharge blood eosinophil count discharge two week later . Adverse event All adverse event encounter study period report case record form . The subject urge report adverse event immetiately appearance . All adverse event grate scale form 1 3 , 1 = mild , 2 = moderate 3 = severe . The investigator also request judge causality adverse event treatment ( 1 = relate , 2 = possibly relate 3 = probably relate ) . If serious adverse effect occur sponsor shall notify within 24 h telephone subsequently write investigator . All serious adverse event must report national regulatory authority within 24 hour occurence . Amendment protocol A new approval ethic committee obtain execution prospective deviation sign protocol . Subject recruitment information Before recruitement , guardian informed aim , character risk study use information text Subject Information ( Appendix 1 ) . After subject sufficient time acquaint information text , investigator seek write consent ( Appendix 2 ) . The original signed consent form retain investigator . The investigator responsible informing study team member sufficient detail study method apply . Ethical aspect This study follow recommendation biomedical research involve human subject ( current revision Declaration Helsinki World Medical Assembly ) . Prior initiation study , protocol , subject information inform consent form submit approve ethic committee Turku University Central Hospital . Data management statistical analysis The data collect statistical software result analyse use statistical test appropriate parallel design . All study correspondence , record document related conduct study distribution investigational drug ( e.g . diskette , case record form , concent form pertinent information ) must retain investigator period least 15 year . References 1 . Ruuskanen O , Ogra PL . Respiratory syncytial virus . Curr Probl Pediatr 1993 ; 23:50-79 . 2 . Martinez FD , Wright AL , Taussig LM , Holmberg CJ , Halonen M , Morgan WJ . Asthma wheeze first six year life . The Group Health Medical Associates . N Engl J Med 1995 ; 332:133-8 . 3 . Habbick BF , Pizzichini MM , Taylor B , Rennie D , Senthilselvan A , Sears MR . Prevalence asthma , rhinitis eczema among child 2 Canadian city : International Study Asthma Allergies Childhood . CMAJ 1999 ; 160:1824-8 . 4 . Hesselmar B , Aberg B , Eriksson B , Aberg N. Asthma child : prevalence , treatment , sensitization . Pediatr Allergy Immunol 2000 ; 11:74-9 . 5 . McIntosh K. Bronchiolitis asthma : possible common pathogenetic pathway . J Allergy Clin Immunol 1976 ; 57:595-604 . 6 . Mertsola J , Ziegler T , Ruuskanen O , Vanto T , Koivikko A , Halonen P. Recurrent wheezy bronchitis viral respiratory infection . Arch Dis Child 1991 ; 66:124-9 . 7 . Rakes GP , Arruda E , Ingram JM , et al . Rhinovirus respiratory syncytial virus wheeze child require emergency care . IgE eosinophil analysis . Am J Respir Crit Care Med 1999 ; 159:785-90 . 8 . Glezen PW , Greenberg SB , Atmar RL , Piedra PA , Couch RB . Impact respiratory virus infection person chronic underlying condition . JAMA 2000 ; 283:499-505 . 9 . Johnston SL , Pattemore PK , Sanderson G , et al . Community study role viral infection exacerbation asthma 9-11 year old child . BMJ 1995 ; 310:1225-9 . 10 . Storr J , Barrell E , Barry W , Lenney W , Hatcher G. Effect single oral dose prednisolonee acute childhood asthma . Lancet 1987 ; 1:879-82 . 11 . Roosevelt G , Sheehan K , Grupp Phelan J , Tanz RR , Listernick R. Dexamethasone bronchiolitis : randomise controlled trial . Lancet 1996 ; 348:292-5 . 12 . Wang EEL , Law BJ , Boucher FD , et al . Pediatric investigator collaborative network infection Canada ( PICNIC ) study admission management variation patient hospitalize respiratory syncytial viral low respiratory tract infection . J Pediatr 1996 ; 129:390-5 . 13 . Ruohola A , Heikkinen T , Waris M , Puhakka T , Ruuskanen O. Intranasal fluticasone propionate prevent acute otitis medium viral upper respiratory infection child . J Allergy Clin Immunol 2000 ; 106:467-71 . 14 . Gustafson LM , Proud D , Hendley JO , Hayden FG , Gwaltney JM Jr . Oral prednisone therapy experimental rhinovirus infection . J Allergy Clin Immunol 1996 ; 97:1009-14 . 15 . Puhakka T , Mäkelä MJ , Malmström K , et al . The common cold : effect intranasal fluticasone propionate treatment . J Allergy Clin Immunol 1998 ; 101:726-31 . 16 . De Boeck K , Van der Aa N , Van Lierde S , Corbeel L , Eeckels R. Respiratory syncytial virus bronchiolitis : double-blind dexamethasone efficacy study . J Pediatr 1997 ; 131:919-21 . 17 . Mäkelä MJ , Puhakka T , Ruuskanen O , Leinonen M , Saikku P , Kimpimäki M , et al . Viruses bacteria etiology common cold . J Clin Microbiol 1998 ; 36 : 539 42 . 18 . Halonen P , Rocha E , Hierholzer J , Holloway B , Hyypiä T , Hurskainen P , Pallansch M. Detection enteroviruses rhinoviruses clinical specimen PCR liquid-phase hybridization . J Clin Microbiology 1995 ; 33:648-53 . 19. van den Hoogen BG , de Jong JC , Groen J , Kuiken T , de Groot R , Fouchier RA , Osterhaus AD . A newly discover human pneumovirus isolate young child respiratory tract disease . Nat Med 2001 ; 7:719-24 . 20 . American Thoracic Society . Recommendations standardize procedure online offline measurement exhale low respiratory nitric oxide nasal nitric oxide adult child - 1999 . Am J Respir Crit Care Med 1999 ; 160 : 2104-17 .</detailed_description>
	<mesh_term>Respiratory Sounds</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>age 3 month 16 year hospitalization expiratory wheeze write informed consent parent Any chronic disease ( allergy asthma ) , e.g . heart disease , immune deficiency , diabetes varicella exposure varicella previously Systemic glucocorticoid 4 week prios study Severe disease need treatment intensive care unit oxygen saturation 92 % despite additional oxygen frequent salbutamol inhalation</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Wheezing</keyword>
	<keyword>virus</keyword>
	<keyword>child</keyword>
</DOC>